These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31609495)

  • 1. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
    Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Tanaka Y; Iwakiri K; Kumada T
    J Gastroenterol Hepatol; 2020 May; 35(5):855-861. PubMed ID: 31609495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
    Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
    Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
    Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
    J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.
    Ueda Y; Kobayashi T; Ikegami T; Miuma S; Mizuno S; Akamatsu N; Takaki A; Ishigami M; Takatsuki M; Sugawara Y; Maehara Y; Uemoto S; Seno H
    J Gastroenterol; 2019 Jul; 54(7):660-666. PubMed ID: 30806783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    Sezaki H; Suzuki F; Hosaka T; Fujiyama S; Kawamura Y; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Gastroenterol; 2019 Oct; 54(10):916-927. PubMed ID: 30903385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
    Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
    J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.
    Ohya K; Imamura M; Osawa M; Teraoka Y; Morio K; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Hiramatsu A; Tsuge M; Aikata H; Hayes CN; Chayama K
    Clin J Gastroenterol; 2020 Apr; 13(2):267-270. PubMed ID: 31463795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report.
    Naganuma A; Sato K; Fukuchi T; Namikawa M; Kakizaki S; Uraoka T; Ohnishi H; Okamoto H
    Clin J Gastroenterol; 2019 Dec; 12(6):592-597. PubMed ID: 31376076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
    Nozaki A; Atsukawa M; Kondo C; Toyoda H; Chuma M; Nakamuta M; Uojima H; Takaguchi K; Ikeda H; Watanabe T; Ogawa S; Itokawa N; Arai T; Hiraoka A; Asano T; Fujioka S; Ikegami T; Shima T; Ogawa C; Akahane T; Shimada N; Fukunishi S; Abe H; Tsubota A; Genda T; Okubo H; Mikami S; Morishita A; Moriya A; Tani J; Tachi Y; Hotta N; Ishikawa T; Okanoue T; Tanaka Y; Kumada T; Iwakiri K; Maeda S;
    Hepatol Int; 2020 Mar; 14(2):225-238. PubMed ID: 32128704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
    Flamm S; Reddy KR; Zadeikis N; Hassanein T; Bacon BR; Maieron A; Zeuzem S; Bourliere M; Calleja JL; Kosloski MP; Oberoi RK; Lin CW; Yu Y; Lovell S; Semizarov D; Mensa FJ
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):527-535.e6. PubMed ID: 30012435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
    Toyoda H; Atsukawa M; Watanabe T; Nakamuta M; Uojima H; Nozaki A; Takaguchi K; Fujioka S; Iio E; Shima T; Akahane T; Fukunishi S; Asano T; Michitaka K; Tsuji K; Abe H; Mikami S; Okubo H; Okubo T; Shimada N; Ishikawa T; Moriya A; Tani J; Morishita A; Ogawa C; Tachi Y; Ikeda H; Yamashita N; Yasuda S; Chuma M; Tsutsui A; Hiraoka A; Ikegami T; Genda T; Tsubota A; Masaki T; Iwakiri K; Kumada T; Tanaka Y; Okanoue T
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1420-1425. PubMed ID: 31950525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.
    Lampertico P; Carrión JA; Curry M; Turnes J; Cornberg M; Negro F; Brown A; Persico M; Wick N; Porcalla A; Pangerl A; Crown E; Larsen L; Yu Y; Wedemeyer H
    J Hepatol; 2020 Jun; 72(6):1112-1121. PubMed ID: 32061651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    Suda G; Hasebe C; Abe M; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Haga H; Ueno Y; Abe K; Takahashi A; Ohira H; Tsukuda Y; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Inoue J; Terasita K; Ohara M; Kawagishi N; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jul; 54(7):641-649. PubMed ID: 30778716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy.
    Grebely J; Dore GJ; Alami NN; Conway B; Dillon JF; Gschwantler M; Felizarta F; Hézode C; Tomasiewicz K; Fredrick LM; Dumas EO; Mensa FJ
    Int J Drug Policy; 2019 Apr; 66():73-79. PubMed ID: 30735896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
    Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
    Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.